Accès à distance ? S'identifier sur le proxy UCLouvain
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Primary tabs
- Open access
- 1.40 M
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès libre |
Publication date | 2022 |
Language | Anglais |
Journal information | "Hematology (Amsterdam, Netherlands)" - Vol. 27, no.1, p. 23-31 (2022) |
Peer reviewed | yes |
e-issn | 1607-8454 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/SLUC - Pôle St.-Luc UCL - SSS/DDUV/MEXP - Médecine expérimentale UCL - (SLuc) Service d'hématologie |
MESH Subject | Biomarkers ; Clinical Decision-Making ; Combined Modality Therapy ; Disease Management ; Disease Susceptibility ; Drug-Related Side Effects and Adverse Reactions ; Hematopoietic Stem Cell Transplantation ; Humans ; Janus Kinase Inhibitors ; Molecular Targeted Therapy ; Nitriles ; Platelet Count ; Primary Myelofibrosis ; Prognosis ; Pyrazoles ; Pyrimidines ; Treatment Outcome |
Keywords | Belgium ; Ruxolitinib ; anemia ; myelofibrosis ; reimbursement ; splenomegaly ; symptom burden ; transplantation |
Links |
Bibliographic reference | Devos, Timothy ; Selleslag, Dominik ; Granacher, Nikki ; Havelange, Violaine ; Benghiat, Fleur Samantha. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.. In: Hematology (Amsterdam, Netherlands), Vol. 27, no.1, p. 23-31 (2022) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/263876 |